Pharma BD Deal Intelligence
A $185M-upfront bet that's actually paying off: AstraZeneca's Eccogene GLP-1 license has advanced from Phase 1 to two completed Phase 2b trials, VISTA and SOLSTICE, both meeting primary endpoints and clearing the path to Phase 3, though the full $1.825B in milestones remains ahead.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca is paying a Chinese biotech $185 million up front, and as much as $1.8 billion more in milestone payments, to license an experimental obesity pill.…
AstraZeneca is paying as much as $2 billion for Chinese rights to a Phase 1 experimental obesity pill, joining Novo Nordisk, Eli Lilly, and a growing list of…
Multiple clinical trial data for elecoglipron (AZD5004/ECC5004), an oral GLP-1 receptor agonist discovered by Eccogene, to be presented at ADA 2026. VISTA and…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
AstraZeneca licensed global rights (ex-China) to ECC5004 from Eccogene in November 2023, an investigational oral once-daily small-molecule GLP-1 receptor agonist for obesity, type 2 diabetes and cardiometabolic conditions. Eccogene received $185M upfront with up to $1.825B in clinical, regulatory and commercial milestones plus tiered royalties. The asset, now named elecoglipron (AZD5004), has since de-risked materially: it advanced from Phase 1 at deal signing to two completed Phase 2b trials -- VISTA in obesity/overweight (NCT06579092, n=310, completed Nov 2025) and SOLSTICE in type 2 diabetes versus semaglutide and placebo (NCT06579105, n=406, completed Dec 2025). Per AstraZeneca's FY2025 results (Feb 2026), both trials met their primary endpoints, supporting progression to Phase 3, with full Phase 2 data presented at the ADA Scientific Sessions on 8 June 2026. The readouts validate the original thesis -- a differentiated oral small-molecule entry into the GLP-1 obesity/T2D race -- though detailed efficacy magnitude vs. Eli Lilly's orforglipron and Novo's oral semaglutide remained to be benchmarked at ADA.
108M US cases/yr · $150.0B Projected global obesity drug market by 2030 (analyst consensus, Goldman Sachs/Morgan Stanley 2023) · ~$2.0B AstraZeneca total deal value ($185M upfront + up to $1.825B milestones)
Obesity affects approximately 41.9% of US adults per the CDC NHANES 2017-2020 cycle (~108 million adults), with severe obesity (BMI >=40) affecting ~9.2% (~24 million). Obesity is a chronic, relapsing disease driving elevated risk of type 2 diabetes, cardiovascular disease, NASH, chronic kidney disease, obstructive sleep apnea, and several cancers. Type 2 diabetes affects approximately 37.3 million US adults (~11.3% of US adults), of whom about 8.5 million are undiagnosed, with ~1.4 million new diagnoses annually. The therapeutic paradigm shifted dramatically with injectable GLP-1 receptor agonists: semaglutide (Novo Nordisk Ozempic/Wegovy), tirzepatide (Eli Lilly Mounjaro/Zepbound, GLP-1/GIP dual), and liraglutide (Saxenda). These produce 15-22% mean weight loss and substantial A1C reductions but require weekly subcutaneous injection, are costly (~$1,000-1,350/month gross), and are supply-constrained. Oral GLP-1 formulations (Rybelsus, oral semaglutide, and Lilly's Phase 3 orforglipron) address injection avoidance, cold-chain logistics, and manufacturing scalability, potentially expanding access into primary-care obesity and T2D markets at lower cost of goods.
The GLP-1 class is the most commercially important therapeutic category of the decade. Injectable incumbents: Novo Nordisk's semaglutide (Ozempic for T2D, Wegovy for obesity) generating ~$21B in 2023; Eli Lilly's tirzepatide (Mounjaro for T2D, Zepbound for obesity, GLP-1/GIP dual) generating $5.2B in 2023 and forecast to surpass Ozempic by 2027; Novo's liraglutide (Victoza/Saxenda); Eli Lilly's dulaglutide (Trulicity, declining ex-patent); and Sanofi's lixisenatide (Adlyxin). Oral GLP-1 competitors to Eccogene's ECC5004: Novo Nordisk's oral semaglutide (Rybelsus, approved 2019, $2.7B in 2023 sales); Eli Lilly's orforglipron (Phase 3, oral non-peptide small molecule, ~14.7% weight loss at 36 weeks); Pfizer's danuglipron (Phase 2, discontinued December 2023 due to tolerability); Structure Therapeutics' GSBR-1290 (Phase 2, oral small molecule); Viking Therapeutics' VK2735 (Phase 2, oral + subQ); and Altimmune's pemvidutide (Phase 2 GLP-1/glucagon). Next-generation injectables include Lilly's retatrutide (GLP-1/GIP/glucagon triple, ~24% weight loss in Phase 2) and Amgen's MariTide (AMG-133, GLP-1R agonist + GIPR antagonist). ECC5004 enters as a once-daily oral small-molecule GLP-1 agonist positioned as a potentially differentiated oral entry with convenience, cost-of-goods, and scalability advantages vs. peptides.
The VISTA Phase IIb trial of elecoglipron (AZD5004/ECC5004) in adults with obesity/overweight (NCT06579092, n=310, 36 weeks) reached primary completion. AstraZeneca reported the primary endpoint was met, supporting Phase 3 progression.
The SOLSTICE Phase IIb trial of oral elecoglipron vs placebo and active comparator semaglutide in type 2 diabetes (NCT06579105, n=406) reached primary completion. Primary endpoint met per AstraZeneca FY2025 results, supporting Phase 3.
Full Phase 2 results for elecoglipron (AZD5004/ECC5004) from the VISTA (obesity) and SOLSTICE (T2D) trials presented at the ADA Scientific Sessions, June 8, 2026. Asset positioned for Phase 3 as a differentiated oral small-molecule GLP-1.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Eccogene (Shanghai) Co., Ltd. (this deal) | 2023 | $2.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Metabolic deals